Test Price
2,900 AED✅ Home Collection Available
OncoPro BRAF Rapid Test in UAE | 2900 AED | Molecular Oncology Diagnostics
Executive Summary & Core Metrics
✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 Accredited Processing with rigorous internal quality controls for FFPE specimens.
✓ Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for archival FFPE blocks and slides, ensuring chain-of-custody integrity.
✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation with referring physician coordination.
✓ Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731.
Test Type: Somatic Mutation Detection
Target Variant: BRAF V600E (c.1799T>A)
Specimen Requirement: FFPE tumor tissue block with ≥10% tumor cellularity
Turnaround Time: 2 working days
Clinical Utility: Targeted therapy guidance for melanoma, colorectal carcinoma, and non-small cell lung cancer
Test Overview & Methodology
The OncoPro BRAF Rapid Test is a validated molecular diagnostic assay employing Real-Time PCR (qPCR) to detect the BRAF V600E activating mutation in formalin-fixed paraffin-embedded (FFPE) tumor tissue. This mutation is a critical predictive biomarker for response to BRAF and MEK inhibitor therapies across multiple solid tumor types. The assay delivers clinically actionable results within 2 working days, enabling timely precision oncology decisions. Testing is performed under strict ISO 15189-accredited protocols with paired positive and negative controls run on every plate.
| Parameter | OncoPro BRAF Rapid Test | Standard BRAF Sequencing (Sanger) |
|---|---|---|
| Methodology | Real-Time PCR (qPCR) – high sensitivity for V600E | Sanger sequencing – lower mutation detection threshold |
| Turnaround Time | 2 working days | 7–10 working days |
| Diagnostic Sensitivity | 99.9% (validated for FFPE) | ~95% |
| Minimum Tumor Content | 10% | 20% or more |
| Price (AED) | 2,900 | 3,500–4,500 |
Physician Insight & Safety Protocols
"The OncoPro BRAF Rapid Test provides a rapid, high-sensitivity detection pathway for the BRAF V600E mutation, which is essential for guiding targeted therapy decisions in melanoma, colorectal, and lung cancer patients. This qPCR-based assay offers superior turnaround time compared to traditional sequencing, enabling oncologists to initiate or adjust BRAF/MEK inhibitor therapy without delay. However, the result must always be interpreted within the full clinical and histopathological context. Any treatment modification should only be made by the managing oncologist after comprehensive evaluation."
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
⚠ Critical Safety Advisory
BRAF mutation test results serve as one component of a complete oncological assessment. Patients must never alter, discontinue, or initiate any prescribed medication based solely on this laboratory result. All therapeutic decisions require direct consultation with the treating oncologist. Laboratory testing must never delay emergency medical care for acute symptoms including uncontrolled pain, bleeding, or respiratory distress.
Exclusion Criteria & Specimen Requirements
- Accepted Specimen: Only FFPE tumor tissue blocks containing ≥10% tumor cellularity are accepted for this assay. Cytology preparations, frozen tissue, plasma, or cell-free DNA specimens are not suitable.
- Insufficient Tumor Content: Specimens with <10% tumor cells will not be processed. Repeat biopsy or macrodissection by a pathologist may be required prior to testing.
- Emergency Situations: Patients experiencing acute bleeding, sudden severe pain, shortness of breath, or other medical emergencies must seek immediate care at the nearest emergency department. Laboratory testing must never delay life-saving intervention.
- Pediatric Consent: For minor patients, informed consent must be obtained from a legal guardian in compliance with UAE federal regulations governing medical consent for minors.
- Data Privacy: All patient health information is processed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Patient FAQ & Clinical Guidance
1. What is the OncoPro BRAF Rapid Test used for?
This test rapidly and accurately detects the BRAF V600E mutation in preserved tumor tissue. A positive result helps your oncologist determine whether targeted therapies such as BRAF inhibitors (vemurafenib, dabrafenib) or MEK inhibitors (trametinib, cobimetinib) may be effective for your specific cancer type, including melanoma, colorectal carcinoma, or non-small cell lung cancer.
2. How should I prepare for providing a tissue sample?
No patient preparation is required. The test uses an existing FFPE tissue block that was collected during a prior biopsy or surgical procedure. Your hospital or clinic will coordinate release of the archival specimen through our Secure Medical Courier Solid Tissue Specimen Retrieval service. No additional invasive procedure is needed.
3. How long does it take to get results?
Results are reported within 2 working days from the time the specimen is received and accessioned in our laboratory. Our molecular diagnostics team processes samples daily, ensuring rapid turnaround to support timely clinical decision-making.
4. Will my insurance cover the cost of this test?
Coverage depends on your specific insurance policy and the clinical indication. Our team can verify direct billing eligibility with your insurer. Contact us via WhatsApp at +971 54 548 8731 for a confidential benefits check before testing.
5. What does a negative BRAF test mean for my treatment options?
A negative result indicates that the BRAF V600E mutation was not detected in the tested tissue sample. This does not rule out other actionable mutations or the possibility of benefit from alternative therapies. Your oncologist may recommend additional genomic testing, including broader next-generation sequencing panels, to identify other potential treatment targets.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
All laboratory testing at DNA Labs UAE is conducted under the regulatory oversight of the Dubai Health Authority (DHA) and adheres to UAE federal standards for medical diagnostics. Patient data confidentiality is strictly maintained in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring all health information is collected, processed, and stored with appropriate technical and organizational security measures. Additionally, Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields governs the secure handling of electronic health records and telemedicine communications. Clinical safety and patient consent procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing that all diagnostic services meet the highest standards of medical accountability and patient rights protection.
DNA Labs UAE maintains DHA Facility License Number 1143 and operates under ISO 15189 quality management principles for medical laboratory accuracy and reliability.
Clinical & Logistical Metadata
| Test Name | OncoPro BRAF Rapid Test (BRAF V600E Mutation Detection by Real-Time PCR) |
| Price (AED) | 2,900 AED |
| Turnaround Time | 2 working days |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tumor Tissue Block (minimum 10% tumor cellularity) |
| Methodology Used | Real-Time PCR (qPCR) with hydrolysis probe detection |
| ICD-10-CM Code | C43.9, C18.9, C34.9 |
| LOINC Code | 59041-3 (BRAF gene mutations found in Tissue) |
| DHA Facility License & Laboratory Address | DHA License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians